Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) saw a large decrease in short interest during the month of September. As of September 30th, there was short interest totalling 3,020,000 shares, a decrease of 13.7% from the September 15th total of 3,500,000 shares. Based on an average daily trading volume, of 346,000 shares, the days-to-cover ratio is currently 8.7 days.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on the company. Oppenheimer assumed coverage on Keros Therapeutics in a research report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 price target on the stock. Guggenheim began coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They set a “buy” rating and a $96.00 price objective on the stock. Bank of America decreased their target price on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Truist Financial reiterated a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Finally, Scotiabank initiated coverage on Keros Therapeutics in a research note on Wednesday. They set a “sector outperform” rating for the company. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Keros Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $90.63.
Check Out Our Latest Analysis on Keros Therapeutics
Insider Activity
Institutional Trading of Keros Therapeutics
Institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its position in Keros Therapeutics by 17.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock worth $80,666,000 after acquiring an additional 176,803 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in Keros Therapeutics during the second quarter valued at approximately $1,118,000. Bank of New York Mellon Corp boosted its holdings in Keros Therapeutics by 18.8% during the second quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock worth $5,410,000 after buying an additional 18,755 shares in the last quarter. Swiss National Bank grew its position in Keros Therapeutics by 22.0% in the first quarter. Swiss National Bank now owns 49,900 shares of the company’s stock worth $3,303,000 after buying an additional 9,000 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Keros Therapeutics in the second quarter valued at $532,000. Institutional investors and hedge funds own 71.56% of the company’s stock.
Keros Therapeutics Stock Down 0.1 %
Keros Therapeutics stock traded down $0.04 during trading hours on Wednesday, hitting $60.35. 7,890 shares of the company traded hands, compared to its average volume of 369,823. Keros Therapeutics has a 1-year low of $27.02 and a 1-year high of $73.00. The firm has a market cap of $2.18 billion, a P/E ratio of -11.73 and a beta of 1.23. The firm’s 50-day simple moving average is $52.45 and its two-hundred day simple moving average is $52.01.
Keros Therapeutics (NASDAQ:KROS – Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The firm had revenue of $0.04 million for the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. During the same quarter last year, the firm posted ($1.27) earnings per share. On average, equities research analysts predict that Keros Therapeutics will post -4.88 earnings per share for the current year.
Keros Therapeutics Company Profile
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
See Also
- Five stocks we like better than Keros Therapeutics
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- How to Invest in the FAANG Stocks
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
- What Are Dividend Achievers? An Introduction
- Salesforce: Have You Seen The Latest Price Target Upgrade?
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.